SBIO.L vs. BIOT.L

Last updated Jul 16, 2026

SBIO.L (Invesco Nasdaq Biotech UCITS ETF) and BIOT.L (L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF) are both Health & Biotech Equities funds - SBIO.L tracks the NASDAQ Biotechnology TR USD while BIOT.L tracks the Solactive Pharma Breakthrough Value Index Net Total Return. Both are passively managed. Over the past 5 years, SBIO.L returned 5.79%/yr vs 2.83%/yr for BIOT.L. Their correlation of 0.81 suggests significant overlap in exposure. SBIO.L charges 0.40%/yr vs 0.49%/yr for BIOT.L.

Performance

SBIO.L vs. BIOT.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SBIO.L achieves a 14.76% return, which is significantly higher than BIOT.L's 8.27% return.

SBIO.L

• 1D: 0.44%
• 1M: 9.18%
• 6M: 12.82%
• YTD: 14.76%
• 1Y: 49.55%
• 3Y*: 17.44%
• 5Y*: 5.79%
• 10Y*: 8.95%

BIOT.L

• 1D: 0.31%
• 1M: 7.79%
• 6M: 7.56%
• YTD: 8.27%
• 1Y: 33.81%
• 3Y*: 10.20%
• 5Y*: 2.83%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

SBIO.L vs. BIOT.L - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
SBIO.L Invesco Nasdaq Biotech UCITS ETF	14.76%	32.89%	-2.00%	6.15%	-11.85%	-0.49%	27.35%	25.54%	-13.75%
BIOT.L L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF	8.27%	36.47%	-5.31%	-9.28%	-8.41%	-3.60%	28.29%	13.02%	-8.12%

Correlation

The correlation between SBIO.L and BIOT.L is 0.87, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.87
Correlation (3Y) Calculated over the trailing 3-year period	0.83
Correlation (5Y) Calculated over the trailing 5-year period	0.83
Correlation (All Time) Calculated using the full available price history since Jan 18, 2018	0.81

The correlation between SBIO.L and BIOT.L has been stable across timeframes, ranging from 0.81 to 0.87 - a consistent structural relationship.

Return for Risk

SBIO.L vs. BIOT.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO.L

SBIO.L Risk / Return Rank: 90
SBIO.L Sharpe Ratio Rank: 90
SBIO.L Sortino Ratio Rank: 90
SBIO.L Omega Ratio Rank: 83
SBIO.L Calmar Ratio Rank: 95
SBIO.L Martin Ratio Rank: 93

BIOT.L

BIOT.L Risk / Return Rank: 67
BIOT.L Sharpe Ratio Rank: 63
BIOT.L Sortino Ratio Rank: 64
BIOT.L Omega Ratio Rank: 55
BIOT.L Calmar Ratio Rank: 83
BIOT.L Martin Ratio Rank: 70

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO.L vs. BIOT.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SBIO.L	BIOT.L	Difference
Sharpe ratio: Return per unit of total volatility	2.43	1.67	+0.77
Sortino ratio: Return per unit of downside risk	3.38	2.39	+1.00
Omega ratio: Gain probability vs. loss probability	1.39	1.28	+0.11
Calmar ratio: Return relative to maximum drawdown	6.45	3.52	+2.92
Martin ratio: Return relative to average drawdown	19.17	10.12	+9.04

SBIO.L vs. BIOT.L - Sharpe Ratio Comparison

The current SBIO.L Sharpe Ratio is 2.43, which is higher than the BIOT.L Sharpe Ratio of 1.67. The chart below compares the historical Sharpe Ratios of SBIO.L and BIOT.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

SBIO.L vs. BIOT.L - Drawdown Comparison

The maximum SBIO.L drawdown since its inception was -39.44%, which is greater than BIOT.L's maximum drawdown of -34.44%. Use the drawdown chart below to compare losses from any high point for SBIO.L and BIOT.L.

Drawdown Indicators

	SBIO.L	BIOT.L	Difference
Max Drawdown Largest peak-to-trough decline	-39.44%	-34.44%	-5.00%
Max Drawdown (1Y) Largest decline over 1 year	-7.65%	-9.55%	+1.90%
Max Drawdown (3Y) Largest decline over 3 years	-26.89%	-19.91%	-6.98%
Max Drawdown (5Y) Largest decline over 5 years	-38.33%	-33.80%	-4.53%
Max Drawdown (10Y) Largest decline over 10 years	-38.33%	—	—
Current Drawdown Current decline from peak	-4.15%	-5.72%	+1.57%
Average Drawdown Average peak-to-trough decline	-16.68%	-13.31%	-3.37%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.58%	3.33%	-0.75%

Volatility

SBIO.L vs. BIOT.L - Volatility Comparison

Invesco Nasdaq Biotech UCITS ETF (SBIO.L) has a higher volatility of 6.42% compared to L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) at 6.08%. This indicates that SBIO.L's price experiences larger fluctuations and is considered to be riskier than BIOT.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SBIO.L	BIOT.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.42%	6.08%	+0.34%
Volatility (6M) Calculated over the trailing 6-month period	15.51%	15.54%	-0.03%
Volatility (1Y) Calculated over the trailing 1-year period	20.35%	20.18%	+0.17%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	21.26%	18.62%	+2.64%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	22.15%	19.50%	+2.65%

SBIO.L vs. BIOT.L - Expense Ratio Comparison

SBIO.L has a 0.40% expense ratio, which is lower than BIOT.L's 0.49% expense ratio.

Dividends

SBIO.L vs. BIOT.L - Dividend Comparison

Neither SBIO.L nor BIOT.L has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both SBIO.L and BIOT.L in my portfolio?

SBIO.L and BIOT.L have a correlation of 0.87, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, SBIO.L or BIOT.L?

On fees, SBIO.L is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, SBIO.L or BIOT.L?

SBIO.L is cheaper with a 0.40% expense ratio, compared with 0.49% for BIOT.L.

What is the main difference between SBIO.L and BIOT.L?

SBIO.L tracks NASDAQ Biotechnology TR USD, while BIOT.L tracks Solactive Pharma Breakthrough Value Index Net Total Return. They also come from different issuers: Invesco and L&G. Their fees differ too: 0.40% for SBIO.L and 0.49% for BIOT.L.